Open an account

Oric Pharmaceuticals

ORIC · NASDAQ

$13.78+$1.06 (+8.33%)TodayMarket closed ·
Prev close $12.72

ORIC analyst rating

BuyConsensus of 12 analysts over the last 12 months. 92% rate it a buy.
  • Strong buy0
  • Buy11
  • Hold1
  • Underperform0
  • Sell0

12-month price target · 15 analysts

Average $21.34 (+54.8% upside)

Low
$14.14
Now
$13.78
High
$28.35

Upgrades and downgrades

The latest rating actions, newest first

ORIC analyst upgrades, downgrades and rating actions
FirmDateActionRating
JP MorganOct 14, 2026MaintainsOverweight
Leerink PartnersOct 5, 2026InitiatesOutperform
BTIGSep 23, 2026InitiatesBuy
HC Wainwright & Co.Aug 10, 2026MaintainsBuy
HC Wainwright & Co.Jun 8, 2026MaintainsBuy
Goldman SachsMay 15, 2026UpgradeBuy
CitigroupMay 5, 2026MaintainsBuy
HC Wainwright & Co.Apr 2, 2026MaintainsBuy
WedbushApr 1, 2026MaintainsOutperform
HC Wainwright & Co.Mar 13, 2026MaintainsBuy

The case for and against

Updated Oct 14, 2026

Bull case

ORIC Pharmaceuticals is attractive because its lead programs address large, validated oncology markets with clear mechanistic differentiation: rinzimetostat appears able to reverse AR resistance in mCRPC while enozertinib shows standout CNS activity in EGFR exon 20 insertion and PACC NSCLC. The company’s clinical data support both efficacy and a cleaner tolerability profile, with rinzimetostat showing 6% grade ≥3 TRAEs, zero dose reductions, and no secondary malignancies to date, while enozertinib posted 100% intracranial ORR across measurable CNS disease. Financially, ORIC ended 2Q26 with about $387.6M in cash and marketable securities, and management expects runway into 2H28, giving it funding to reach multiple catalysts.

Bear case

ORIC Pharmaceuticals is a clinical-stage biotech with no commercial revenue, so its valuation depends almost entirely on pipeline execution, especially MEVPRO-1 and the probability that ORIC-944 and ORIC-114 can clear pivotal development and regulatory hurdles. The bearish case is that a readout miss would undermine the mechanistic thesis for PRC2 inhibition in post-abiraterone mCRPC, while the company still faces meaningful safety, efficacy, pricing, and approval risks across its assets. Even with a focused 2025 pipeline prioritization and a 20% workforce reduction in 4Q25, ORIC may still need additional financing, creating dilution risk before any product can generate value.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.